List view / Grid view
In the continuing battle against COVID-19, researchers now must identify the best candidates for vaccines and convalescent serum therapies against the virus.
Horizon Discovery have developed their 3D OncoSignature™ spheroid screening service that consists of a panel of 200 cell lines. In this application note they demonstrate the ability of parallel 2D and 3D OncoSignature primary screens to identify known compounds with enhanced activity under 3D conditions.
Researchers have revealed that the antibiotic concanamycin A targets a protein called Nef, allowing the immune system to destroy HIV in cells.
Sign up for free weekly 5-10 min videos from Horizon’s expert cell line engineers to help you improve your CRISPR editing experiments.
This webinar explains how synthetic guide RNAs are stable, eliminate cloning and sequencing steps, and avoid innate immune responses and cytotoxicity.
The World Health Organization (WHO) identifies leishmaniasis as a neglected tropical disease for which new treatments are vitally needed. Leishmaniasis primarily affects people in South America, East Africa and Asia, especially those weakened by malnutrition and poverty. To help those with this disfiguring and potentially life-threatening parasitic disease, the European…
We have entered a new era of drug discovery where the use of advanced cell models such as multi-cellular co-cultures, stem cells and CRISPR-based screens can lead to the next generation of therapeutics.
The clinical success rate of new oncology drugs is low compared to other diseases. One contributing factor is likely to be the testing systems used, particularly two-dimensional (2D) monolayer assay formats, which are the traditional mainstay of high-throughput compound screening.
Horizon article on the recipe for success for CRISPR editing in T cells.
This article explains how to plan a gene-editing experiment. How to choose your biological system and what reagents to get for your experimental aim.
The Octet® systems provide broad applications in high throughput to help bispecific and multi-specific antibody discovery.
This application note by ForteBio explores antibody fragment molecule (Fab) for process development and quality control.
In this In-Depth Focus find articles exploring the roles of key proteins implicated in Alzheimer's disease and a new technology enabling the identification of novel cancer biomarkers.
Modify the genome and modulate expression of genes within human iPS cells with Dharmacon™ Edit-R CRISPR reagents.
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…
